Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2021-05-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
四环生物2020年年度股东大会法律意见书
Regulatory Filings
2021-05-07 Chinese
江苏四环生物股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard effective from January 1, 2021. It details the reasons for the change, the main content of the new policy, its impact on the company, and includes opinions from the board, independent directors, and the supervisory board. The document is relatively short (1536 characters) and serves as a formal announcement of an accounting policy change rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-29 Chinese
一季报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of the 2021 first quarter report and an accounting policy change. It is titled as a board meeting resolution announcement and includes voting results. The document does not contain the actual financial report or detailed financial data but announces the approval of such a report. The document length is short (487 characters), and it is an announcement of board decisions rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting resolutions and decisions.
2021-04-29 Chinese
江苏四环生物股份有限公司关于控股孙公司签署代理协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio Co., Ltd. regarding the signing of an agency agreement by its controlling subsidiary. It details the parties involved, the contract terms, and the strategic impact on the company. There is no financial data, no mention of a report or filing, and the document is relatively short (1434 characters). It is an announcement about a business transaction rather than a financial report or regulatory filing. The content fits best under a general regulatory announcement category rather than a specific financial report or management change. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-29 Chinese
2021年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏四环生物股份有限公司 2021 年第一季度报告正文' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2021 First Quarter Report'. It contains detailed financial data such as revenue, net profit, cash flow, and other financial indicators for the first quarter of 2021. The document includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarterly report. There is no indication that this is an announcement of a report or a certification letter. The length of the document (6212 characters) and the detailed financial data confirm it is a substantive financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-29 Chinese
独立董事意见
Regulatory Filings Classification · 95% confidence The document is a short statement from independent directors regarding a change in accounting policy. It confirms the reasonableness and compliance of the change with accounting standards and laws, and states that it does not harm shareholders' interests. The document is only 231 characters long and does not contain any financial data or detailed report content. It is essentially an opinion or certification related to accounting policy change. According to the rules, such officer certifications or attestations should be classified as Regulatory Filings (RNS).
2021-04-29 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.